



Kentucky Hospital Research & Education Foundation Emergency Preparedness Update for April 20, 2021

Beshear updates Healthy at Work requirements; Reports 231 cases, 4 deaths, 3.46% positivity

(KyForward News) Gov. Andy Beshear and Dr. Steven Stack, commissioner of the Kentucky Department for Public Health, updated Kentuckians on the state's Healthy at Work requirements aimed at keeping all employees and their families safe.

The Healthy at Work [minimum requirements list](#) has been simplified and now applies to all businesses.

"We have fought really hard to get where we are – a much better place than in the fall and winter – allowing us to streamline some of our guidance," said Gov. Beshear. "I hope people are able to enjoy some of these capacity increases. We can do so safely if we continue to wear our masks."

The minimum requirements list includes specifications for:

- **Physical distancing;**
- **Facial coverings;**
- **Hand washing and sanitizing;**
- **Ventilation;**
- **Telework;**
- **Common areas; and**
- **Daily temperature/health checks.**

Events with 1,000 or fewer people in a single space are limited to 60% capacity, or the maximum number of people that allows for physical distancing. Events with more than 1,000 people in a single space are limited to 50% capacity, or the maximum number of people that allows for physical distancing.

Beshear reported the following COVID-19 numbers:

Kentuckians vaccinated (have received at least one dose): 1,665,196

New cases today: 231

New deaths today: 4

New audit deaths: 5

Positivity rate: 3.46%

Total deaths: 6,347

Currently hospitalized: 402

Currently in ICU: 121

Currently on ventilator: 43

Full story: <https://www.kyforward.com/beshear-updates-healthy-at-work-requirements-reports-231-cases-4-deaths-3-46-positivity/>

FDA Revokes EUA for bamlanivimab (when administered alone)

(ASPR) On Friday, April 16, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) for bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients who are at high risk of disease progression or hospitalization. Please see the full FDA statement [here](#).

REGEN-COV as well as bamlanivimab and etesevimab (administered together) continue to be available under EUA. There is no shortage of monoclonal antibody product. Sites that are administering monoclonal antibodies can order bamlanivimab and etesevimab, etesevimab to pair with the current supply of bamlanivimab that the site has available, or REGEN-COV from the authorized distributor using the [direct ordering](#) process.

ASPR will continue to work with our Federal partners on monoclonal antibody therapies authorized for emergency use and will provide updates as they become available.

Please contact COVID19Therapeutics@hhs.gov with any questions.

CDC vaccine advisers will meet Friday to discuss the J&J vaccine. Here's what could happen next

<https://www.cnn.com/2021/04/20/health/jj-acip-meeting-whats-next/index.html>

The KHEREF Emergency Preparedness Update is assembled several times a week. When events make it necessary, the Update may be sent out several times a day to keep our hospital and the healthcare community advised on preparedness news and information. Most of this information is compiled from open sources, and where possible reference links will be provided. There is an archive of [Emergency Preparedness Updates available here](#). If you would like to add or delete, or have something you would like to contribute to a future edition of the Emergency Preparedness Update, please contact Preparedness@kyha.com (include your current email address). The preparedness program for the Kentucky Hospital Association (KHA) and KHEREF are supported by US DHHS ASPR HPP funds through a contract with Kentucky Public Health.